Scientists test new drug duo to reawaken immune system against stubborn tumors
NCT ID NCT07404332
Summary
This early-stage study is testing a new combination of two drugs for people with advanced solid tumors that have stopped responding to standard immunotherapy. The goal is to find the safest and most effective dose of the drug 5-Azacitidine when added to a patient's current immunotherapy. Researchers will enroll about 35 adults to see if this combination can help control cancer growth in patients who have run out of other options.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Iowa Health Care
Iowa City, Iowa, 52242, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.